Similar articles for PMID: 17389539

Year	Number of Results
1974	1
1978	1
1983	1
1984	2
1987	1
1988	1
1989	3
1993	2
1994	2
1996	1
1997	2
1999	2
2000	5
2001	3
2002	6
2003	22
2004	24
2005	21
2006	39
2007	38
2008	25
2009	14
2010	22
2011	24
2012	16
2013	24
2014	31
2015	24
2016	20
2017	28
2018	17
2019	17
2020	10
2021	10
2022	5
2023	1
2024	0

1

Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.

Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Mintzer IL, et al. Ann Fam Med. 2007 Mar-Apr;5(2):146-50. doi: 10.1370/afm.665. Ann Fam Med. 2007. PMID: 17389539 Free PMC article. Clinical Trial.

2

Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.

Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D; Buprenorphine/Naloxone Collaborative Study Group. Fudala PJ, et al. N Engl J Med. 2003 Sep 4;349(10):949-58. doi: 10.1056/NEJMoa022164. N Engl J Med. 2003. PMID: 12954743 Free article. Clinical Trial.

3

Using buprenorphine for outpatient opioid detoxification.

Manlandro JJ Jr. Manlandro JJ Jr. J Am Osteopath Assoc. 2007 Sep;107(9 Suppl 5):ES11-6. J Am Osteopath Assoc. 2007. PMID: 17908825 Review.

4

Opioid Addiction Treatment Using Buprenorphine-Naloxone In A Community-Based Internal Medicine Practice.

Van Doren BA, Foulks-Rodriguez KA, Yarborough W. Van Doren BA, et al. J Okla State Med Assoc. 2015 Jul;108(7):303-9. J Okla State Med Assoc. 2015. PMID: 26390769

5

Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.

Turner BJ, Laine C, Lin YT, Lynch K. Turner BJ, et al. Arch Intern Med. 2005 Aug 8-22;165(15):1769-76. doi: 10.1001/archinte.165.15.1769. Arch Intern Med. 2005. PMID: 16087826

6

Initial strategies for integrating buprenorphine into HIV care settings in the United States.

Sullivan LE, Bruce RD, Haltiwanger D, Lucas GM, Eldred L, Finkelstein R, Fiellin DA. Sullivan LE, et al. Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S191-6. doi: 10.1086/508183. Clin Infect Dis. 2006. PMID: 17109306 Review.

7

Buprenorphine for office-based treatment of patients with opioid addiction.

Manlandro JJ Jr. Manlandro JJ Jr. J Am Osteopath Assoc. 2005 Jun;105(6 Suppl 3):S8-13. J Am Osteopath Assoc. 2005. PMID: 16118361 Review.

8

The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?

Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA. Sullivan LE, et al. Drug Alcohol Depend. 2005 Jul;79(1):113-6. doi: 10.1016/j.drugalcdep.2004.12.008. Drug Alcohol Depend. 2005. PMID: 15943950 Clinical Trial.

9

Helping 'them': our role in recovery from opioid dependence.

Loxterkamp D. Loxterkamp D. Ann Fam Med. 2006 Mar-Apr;4(2):168-71. doi: 10.1370/afm.518. Ann Fam Med. 2006. PMID: 16569721 Free PMC article.

10

The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.

Mammen K, Bell J. Mammen K, et al. Expert Opin Pharmacother. 2009 Oct;10(15):2537-44. doi: 10.1517/14656560903213405. Expert Opin Pharmacother. 2009. PMID: 19708849 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

422 results

Results by year